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Abstract
IFI16, a nuclear pathogenic DNA sensor induced by several pro-inflammatory cytokines, is a multifaceted protein with
various functions. It is also a target for autoantibodies as specific antibodies have been demonstrated in the sera of patients
affected by systemic autoimmune diseases. Following transfection of virus-derived DNA, or treatment with UVB, IFI16
delocalizes from the nucleus to the cytoplasm and is then eventually released into the extracellular milieu. In this study,
using an in-house capture enzyme-linked immunsorbent assay we demonstrate that significant levels of IFI16 protein can
also exist as circulating form in the sera of autoimmune patients. We also show that the rIFI16 protein, when added in-vitro
to endothelial cells, does not affect cell viability, but severely limits their tubulogenesis and transwell migration activities.
These inhibitory effects are fully reversed in the presence of anti-IFI16 N-terminal antibodies, indicating that its extracellular
activity resides within the N-terminus. It was further demonstrated that endogenous IFI16 released by apoptotic cells bind
neighboring cells in a co-culture. Immunofluorescence assays revealed existence of high-affinity binding sites on the plasma
membrane of endothelial cells. Free recombinant IFI16 binds these sites on HUVEC with dissociation constant of 2.7 nM,
radioiodinated and unlabeled IFI16 compete for binding sites, with inhibition constant (Ki) of 14.43 nM and half maximal
inhibitory concentration (IC50) of 67.88 nM; these data allow us to estimate the presence of 250,000 to 450,000 specific
binding sites per cell. Corroborating the results from functional assays, this binding could be completely inhibited using
anti-IFI16 N-terminal antibody, but not with an antibody raised against the IFI16 C-terminal. Altogether, these data
demonstrate that IFI16 may exist as circulating protein in the sera of autoimmune patients which binds endothelial cells
causing damage, suggesting a new pathogenic and alarmin function through which this protein triggers the development
of autoimmunity.
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Introduction
A wealth of data now exists demonstrating the critical role of
interferons (IFNs) in the pathogenesis and perpetuation of
autoimmunity [1–5]. Genomic studies have revealed that type I
IFN inducible genes are markedly overexpressed in the peripheral
blood of patients with systemic autoimmune diseases including
Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc),
and Sjogren’s Syndrome (SjS) [6–8]. In SLE patients, this so-called
‘‘IFN signature’’ is generally associated with active disease states,
renal, and CNS involvement [9]. Together, these findings have led
to the hypothesis that type I IFNs (IFN-a and IFN-b) may be the
master cytokines responsible for the initiation and progression of
the autoimmune process [10–12].
One family of IFN-inducible genes is the HIN200/Ifi200 gene
family, which encodes evolutionary related human (IFI16, IFIX,
MNDA, and AIM2) and murine (Ifi202a, Ifi202b, Ifi203, Ifi204,
Ifi205/D3, and Ifi206) proteins. The common domain architec-
ture of this protein family consists of one or two copies of the HIN
domain (a 200 amino acid repeat) and an N-terminal PYD
domain, also named PAAD, DAPIN, or Pyrin. The PYD domain,
commonly found in death-family proteins, like Pyrin and ASC, is
present in the N terminus of most HIN200 proteins, suggesting a
role of these proteins in inflammation and apoptosis [13,14]. The
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IFI16 protein is specifically expressed in vascular endothelial cells,
keratinocytes, and hematopoietic cells [15] and has been recently
shown to act as a foreign DNA sensor [16–19]. We have
previously demonstrated that oxidative stress and various proin-
flammatory cytokines can also trigger IFI16 nuclear expression
[20] and [21]. In addition, a role of IFI16 as an inducer of
proinflammatory molecules (e.g. ICAM-1, RANTES, and CCL20)
and apoptosis in endothelial cells has also been observed,
supporting its role in the initial steps of the inflammatory processes
that precede the onset of autoimmune syndromes [22–24]. IFI16
protein is also a target for autoantibodies. Anti-IFI16 autoanti-
bodies have been demonstrated in the sera of patients affected by
systemic autoimmune diseases including SLE, SSc, and SjS. [25–
28]. To explain this observation, we hypothesized that its
overexpression and extranuclear appearance during cell death
contribute to its release into the extracellular milieu and eventually
to the induction of specific autoantibodies. Consistent with this
hypothesis, we have recently demonstrated in vitro that the IFI16
protein, normally detected in the nucleus of human keratinocytes,
can be induced to appear in the cytoplasm under conditions of UV
light-induced cell injury and then released in the culture media. A
similar situation was also found in tissue sections of skin biopsies
from patients with SLE. In this model, IFI16 expression was up-
regulated and mislocalized to the cytoplasm, suggesting that
aberrant expression of IFI16 in epithelial and inflammatory cells
can also play a role in triggering an autoimmune response in vivo
[29]. However, since IFI16 was previously thought to be restricted
to the intracellular environment, and in particular to the nucleus
[13,30], all the recognized biological activities of IFI16, as well as
their possible links with human pathologies, have only been
considered in relation to this localization. Indeed, all the in vitro
studies published to date have involved the overexpressing or
down-regulation of IFI16 in different cell models, and the
modulation of IFI16 has always been monitored intracellularly
(i.e. using cell extracts or by directly analyzing the presence of
IFI16 inside the cells, for instance using immunofluorescence
techniques).
In the present study, using an in-house enzyme-linked
immunosorbent assay (ELISA) we demonstrate the presence of
detectable amounts of a circulating form of IFI16 in the sera from
patients affected by autoimmune disorders. We also provide
experimental evidence showing that the extracellular form of
IFI16 is directly involved in specifically down-regulating the
migratory activities and tube morphogenesis of endothelial cells.
Moreover, we demonstrate the ability of IFI16 to bind to the
plasma membrane of endothelial cells and, by means of binding
kinetics analyses, we show for the first time, evidence of high
affinity IFI16 binding sites on these cells. These data point to a




Human umbilical vein endothelial cells (HUVECs), were grown
in Endothelial cell growth medium-2 (EGM-2) (Lonza, Italy) with
2% Fetal Bovine Serum (Sigma-Aldrich, Milan, Italy) and
supplemented with 1% Penicillin-Streptomycin solution (Sigma-
Aldrich, Milan, Italy) as previously described [31]. Low passage
human dermal fibroblasts, HDF (ATCC), mouse fibroblasts, 3T3
(ATCC), HeLa (ATCC) and HaCaT (ATCC) cells were grown in
Dulbecco’s modified Eagle’s medium (DMEM) (Sigma-Aldrich,
Milan, Italy) supplemented with 10% fetal bovine serum and 2%
Penicillin-Streptomycin solution Unless specified, all cells were
grown at 37uC and 5% CO2.
Recombinant Proteins
The entire coding sequence of the b isoform of human IFI16
was subcloned into the pET30a expression vector (Novagen,
Madison, WI) containing an N-terminal histidine tag. Protein
Expression and affinity purification, followed by fast protein liquid
chromatography (FPLC), were performed according to standard
procedures. The purity of the proteins was assessed by 10%
sodium dodecyl sulfate-polyacrylamide gel electrophoresis. As
negative controls in enzyme-linked immunosorbent assays
(ELISA), the polypeptide encoded by the pET30a empty vector
(control peptide) was expressed and purified according to the same
protocol.
Patients and Determination of Human Extracellular IFI16
by Capture ELISA
The study groups comprised patients suffering from Systemic
Sclerosis, (n = 50), Systemic Lupus Erythematosus, (n = 100),
Sjogren Syndrome, (n = 49), Rheumatoid Arthritis (n = 50) and
Non-SLE Glomerulonephritis (n = 46). As controls, we investigat-
ed sera from 116 sex- and age-matched healthy subjects. Written
informed consent was obtained from all subjects according to the
Declaration of Helsinki and approval was obtained from local
ethics committees of corresponding hospital.
For the determination of circulating extracellular IFI16, a
capture ELISA was employed. Briefly, polystyrene micro-well
plates (Nunc-Immuno MaxiSorp; Nunc, Roskilde, Denmark) were
coated with a home-made polyclonal rabbit-anti-IFI16 antibody
(478–729 aa). Subsequently, plates were washed and free binding
sites then saturated with PBS/0.05% Tween/3% BSA. After
blocking, sera were added to plates in duplicate. Purified 6His-
IFI16 protein was used as the standard and BSA served as the
negative control. The samples were washed, monoclonal mouse
anti-IFI16 antibody (Santa Cruz, sc-8023) added, and then
incubated for 1 h at room temperature. After washing, horseradish
peroxidase-conjugated anti-mouse antibody (GE Healthcare Eu-
rope GmbH, Milan, Italy) was added. Following the addition of
the substrate (TMB; KPL, Gaithersburg, MD, USA), absorbance
was measured at 450 nm using a microplate reader (TECAN,
Mannedorf, Switzerland). Concentrations of extracellular IFI16
were determined using a standard curve for which increasing
concentrations of purified 6His-IFI16 were used.
Cell Viability Assay
Cells were seeded at a density of 16104/well in a 96-well culture
plate. After 24 hours, cells were treated with different doses (10, 25
or 50 mg/ml) of recombinant IFI16 protein (IFI16), mock-treated
using the same volume of vehicle as each IFI16 dose (Mock), or left
untreated (NT). Where indicated, different doses (1.75 mgr or
3.5 mgr) of antibody against IFI16 were added. Forty-eight hours
after treatment, cell viability was determined using the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
(Sigma-Aldrich, Milan, Italy) method, as previously described [32].
Tube Morphogenesis Assay
HUVEC were seeded in complete medium in 60-mm culture
dishes coated with 0.2% gelatin (Sigma-Aldrich, Milan, Italy) and
were treated for 48 h with different doses (10 or 25 mg/ml) of
recombinant IFI16 protein (IFI16). As negative controls, cells were
treated with the same volumes of vehicle (Mock) used for each
IFI16 dose or left untreated (NT). Where indicated, different doses
Extracellular IFI16 Protein as Signal of Damage
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(1.75 mgr or 3.5 mgr) of antibody against IFI16 were added. Tube
morphogenesis assay was performed as described in [33]. Briefly, a
24-microwell plate, pre-chilled at 220uC, was coated with 250 ml/
well of Matrigel Basement Membrane (5 mg/ml; Becton and
Dickinson, Milan, Italy) and then incubated at 37uC for 30 min
until solidified. HUVEC (86104 cells/500 ml per well) were seeded
onto the matrix and allowed to incubate at 37uC in 5% CO2.
Plates were photographed after 6 h using a Leica inverted
microscope.
Migration Assay
Twenty-four well transwell inserts with an 8 mm pore size
(Corning B.V. Life Sciences, Amsterdam, The Netherlands) were
coated with a thin layer of gelatin (0.2%). HUVECs cultured in
EGM-2 with 2% FBS and pre-treated with different concentra-
tions of IFI16 recombinant protein or mock- or untreated for 48
hours were washed twice with PBS, trypsinized and plated into the
upper chambers (46105 cells) resuspended in 200 ml of EBM-2
(Lonza, Italy), 0.1% BSA (Sigma-Aldrich, Milan, Italy) plus IFI16
recombinant protein or mock solution (the same amounts as in the
48 h pre-treatment). The lower chambers were filled with 600 ml
EGM2 containing VEGF and bFGF (as chemo-attractants)
(Sigma-Aldrich, Milan, Italy), 2% FBS, and IFI16 recombinant
protein or mock solution (the same amounts as in the upper
chamber). The chambers were incubated for 5 h at 37uC in a
humidified atmosphere containing 5% CO2. After incubation,
cells on the upper side of the filter were removed. The cells that
had migrated to the lower side of the filter were washed twice with
PBS, fixed with 2.5% glutaraldehyde (Sigma-Aldrich, Milan, Italy)
for 20 min at room temperature, and stained with 0.5 ml crystal
violet (0.1% in 20% methyl alcohol solution) (Sigma-Aldrich,
Milan, Italy). After washes, color was developed in 10% acetic acid
and read in duplicate at 540 nm on a microplate reader (Victor 3;
Perkin-Elmer, Boston, MA).
rIFI16-FITC Membrane Binding and Confocal Microscopy
HUVEC were seeded in 24-well plate in the presence of glass
cover-slip and were grown overnight in presence of 1 mg/ml
tunicamycin (Sigma-Aldrich, Milan, Italy) in EGM-2 medium with
2% FBS and antibiotics. The cells were washed twice with cold
PBS and incubated with increasing concentrations (10 nM,
20 nM, 30 nM) of FITC labeled rIFI16 (FluoReporterH FITC
Protein Labeling Kit by Invitrogen) for 90 minutes at 4uC. Later
the cells were washed twice with cold PBS and were fixed using
2% para-formaldehyde solution for 4 minutes. The PBS wash was
repeated thrice and the coverslips were mounted on glass slides
using ProLongH Gold Antifade Reagent by Invitrogen. The slides
were observed using Leica Confocal Microscope at 490 nm
excitation wavelength for FITC in one channel while trans-
illuminated light in the other.
Co-Culturing and Immunofluorescence
Co-culturing was performed with HeLa cells and HUVEC, as
described in Koristka S. et.al [34]. 105 HeLa cells were seeded in
24 well-plate coated with 0.2% Gelatin in the presence of glass
cover-slip and grown over-night in DMEM with 10% FCS at
37uC, 5% CO2. The cells were washed, suspended in PBS and
lethally irradiated with UV-B lamp (HD 9021; Delta Ohm S.r.l.,
Padova, Italy). The dosage of 1000 Wm2 was counted using a
UVB irradiance meter cosine corrector with spectral range of 280–
319 nm (LP 9021 RAD; Delta Ohm). Followed by this, 56104
HUVEC were added in the same well, grown in EGM-2 with 2%
FCS until ready. Immunofluorescence was performed after 24 hr,
36 hr and 48 hr using a home-made anti-IFI16 polyclonal as
primary antibody and Alexa488- anti-rabbit (GE Healthcare) as
secondary antibody. The cells were then fixed with 2% para-
formaldehyde (Sigma-Aldrich, Milan, Italy), permeabilized with
0.2% Triton X-100 (Sigma-Aldrich, Milan, Italy) and nuclear
stained with 1 mg/ml propidium iodide (Sigma-Aldrich, Milan,
Italy). The coverslips were mounted on glass slides using ProLongH
Gold Antifade Reagent by Invitrogen and the cells were observed
by Leica confocal microscope.
Radioiodination of rIFI16 and Binding Assays
Iodination Beads were purchased from Thermo Fischer
Scientific Inc. (Rockford, IL, USA) and used according to
manufacturer’s instructions. Briefly, two dry beads were washed
with rIFI16 elution buffer (50 mM HEPES pH 7.5; 1 M NaCl)
(Sigma-Aldrich, Milan, Italy), soaked dry and was incubated for 5
minutes with the solution of carrier-free 2 mCi Na125I (Perkin
Elmer Italia, Milan, Italy) and diluted in elution buffer. Later
200 mg of rIFI16 was added and incubated for 15 minutes. The
labeling reaction was passed through Zeba Spin Desalting
Columns (Thermo Fischer Scientific Inc.) to remove excess
Na125I or unincorporated 125I from the iodinated protein. The
concentration of the final radioiodinated [125I]-rIFI16 was
calculated using the following formula, where ‘C’ is the cpm
counted, ‘V’ is volume of solution counted in ml and ‘Y’ is the
specific activity of the radioligand in cpm/fmol.
Concentration of [125I]-rIFI16 in (pM)= [‘C’cpm/‘Y’cpm/
fmol]/‘V’ml.
Binding assay was performed as described in [35,36], 105 cells/
well were seeded and attached in a 24-well plate with. Once ready,
the medium was removed and the cells were washed with PBS.
Further they were re-suspended with increasing concentrations of
[125I]-rIFI16 (1–32 nM) within different wells in the presence of
200 nM unlabeled rIFI16 for Non-Specific Binding. Separately,
other wells were re-suspended with [125I]-rIFI16 (1–32 nM)
without any unlabeled rIFI16 for total binding. The incubation
was performed at 4uC for 90 minutes. Later, the cells were washed
with PBS to remove any loosely bound ligand and were then
suspended in warm 1% SDS (Sigma-Aldrich, Milan, Italy) for 5
minutes. The SDS lysate of the cells was then measured on Cobra
II Series Auto-Gamma Counter. All the experiments were carried
out in triplicates and the data was analyzed using non-linear
regression equations from GraphPad Prism with 95% confidence
intervals.
Competition and Inhibition of [125I]-rIFI16 Binding
For binding competition experiments, cells were seeded into 96-
well plates at a density of 104 cells/well. The medium was
removed and cells were washed with PBS. HUVEC were then
incubated at 4uC for 90 minutes with unlabeled rIFI16 (10–
1000 nM) in the presence of 10 nM [125I]-rIFI16. Binding
inhibition was carried out overnight by incubating 10 nM [125I]-
rIFI16 with varying concentrations (10–1000 nM) of anti-IFI16
polyclonal N-terminal (1–205 aa) or C-terminal (478–729 aa)
antibodies at 4uC. This mixture was then added to 104 HUVEC
and incubated for 90 minutes at 4uC. The loosely bound ligand
was removed by washing twice with PBS, and cells were then
detached using warm 1% SDS and the levels of [125]-rIFI16-
binding to HUVEC assessed using a Cobra II Series Auto-Gamma
Counter. The data were analyzed using non-linear regression
equations in GraphPad Prism under 95% confidence intervals.
Statistical Analysis
All statistical tests were performed using GraphPad Prism
version 5.00 for Windows (GraphPad, La Jolla, CA, USA).
Extracellular IFI16 Protein as Signal of Damage
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Positivity cut-off values for anti-IFI16 antibodies were calculated
as the 95th percentile for the control population and the Kruskal-
Wallis test was used to measure associations. To test the effects of
recombinant IFI16 protein (rIFI16) on biological functions of
primary endothelial cells one-way analysis of variance (ANOVA)
with Bonferroni adjustment for multiple comparisons was used.
Results
Serum Levels of IFI16 Protein are Increased in Patients
with Systemic Autoimmune Diseases
Sera were harvested from patients suffering from systemic
autoimmune diseases characterized by endothelial dysfunction,
including SSc, SLE, SjS, and RA. IFI16 serum levels were
quantified using an in-house sandwich ELISA and compared with
age- and sex-matched healthy controls. All absorbance levels were
in the range of assay linearity. With the cut-off value set to the 95th
percentile of the control population (27 ng/ml), mean IFI16 levels
were significantly increased in patients with SSc, SLE, RA, and
SjS compared to the control group (4.7 ng/ml) (SSc: 25.4 ng/ml,
p,0.001; SLE: 23.5 ng/ml, p,0.001; RA: 222 ng/ml, p,0.001;
SjS: 88.2 ng/ml, p,0.001). Of note, the sera from RA patients
displayed the highest levels of circulating free protein. IFI16 levels
above the 95th percentile for control subjects were observed in
34% of SSc, 37% of SLE, 47% of SjS, and 56% of RA patients
(Figure 1). By contrast, IFI16 levels in non-SLE GN patients did
not show any significant difference in comparison with healthy
controls. Since the objective of this part of the study was limited to
demonstrate the presence of circulating IFI16 in patients’ sera for
justifying the rest of the in vitro studies, correlation with
clinicopathological parameters was behind the aim of these studies
and was not performed.
Effects of Extracellular IFI16 on Different Functions of
Primary Endothelial Cells
Abnormalities in angiogenesis are frequently present in systemic
autoimmune diseases and may lead to tissue damage and
premature vascular disease [37]. To verify whether extracellular
IFI16 was also involved in this pathogenic process, HUVEC were
treated with increasing concentrations of recombinant IFI16
protein (rIFI16) (10, 25 or 50 mg/ml), mock-treated with the same
volumes of vehicle (Mock), or left untreated (NT) and then assessed
for cell viability at 48 hours incubation time by MTT assay. As
shown in Figure 2A, the addition of endotoxin-free rIFI16 protein
did not reduce the amount of viable adherent cells when compared
to mock or untreated cells at the concentration of 10 and 25 mg/
ml, respectively. At the highest concentration used (50 mg/ml), a
slight reduction in cell viability was observed, and consequently
the following studies were conducted with the lower doses.
Next, to test whether the addition of rIFI16 to culture media
altered other biological parameters of endothelial cells, HUVEC
were treated as described for the assessment of cell viability (MTT
assay) and then analyzed for their tubule morphogenesis and
chemotactic activities. As shown in Figure 2B, exogenous
administration of 25 mg/ml rIFI16 severely limited tubulogenesis,
with most cells generating incomplete tubules or aggregating into
clumps. The extent of angiogenesis was quantified by counting the
intact capillary-like tubules called as Lumens, which showed 75%
decrease in its numerical value, as well as the number of
interconnecting branch points showing 77% decrease.
(Figure 2B). These effects were less pronounced when a lower
dose of 10 mg/ml rIFI16 was used with 22% and 15% decrease
respectively. In contrast, untreated or mock-treated HUVEC
plated onto matrigel supported the formation of an extensive
interconnecting polygonal capillary-like network.
Next, we evaluated the effects of rIFI16 on the migration phase
of angiogenesis in a transwell migration assay routinely used to
study cell migration in response to specific stimuli. HUVECs
untreated, mock-treated, or incubated with rIFI16 (10 or 25 mg/
ml) for 48 h were transferred into transwell migration chambers.
As shown in Fig. 2C, only a small population of HUVECs cultured
in the presence of 25 mg/ml rIFI16 were able to migrate through
the chamber (30% of migration), whereas mock-treatment resulted
in considerable migration (95% and 87% for 10 mg/ml and
25 mg/ml, respectively).
Taken together, these results demonstrate the capability of
extracellular rIFI16 to impair physiological functions of endothe-
lial cells, such as the differentiation phases responsible for tube
morphogenesis and migration.
Anti-N-terminus IFI16 Antibodies Neutralize the
Cytotoxic Activity of IFI16
To demonstrate that the effects exerted by IFI16 protein on
target cells were specific and not a consequence of cell cytotoxicity,
HUVEC were treated with 25 mg/ml rIFI16 in the presence or
absence of specific rabbit polyclonal antibodies recognizing the N-
terminal or the C-terminal domain of IFI16 protein. HUVEC
incubated with rIFI16 in the presence of normal rabbit IgG were
used as the positive control. As described in the previous section,
rIFI16 severely affected the capability of endothelial cells to
generate microtubules as well as their transwell migration activity,
while the same effects were observed in presence of normal rabbit
IgG (Figure 3A and 3B). In contrast, the presence of anti-N-
terminus antibodies reduced the Lumens by 16%, Branch Points
by 5% and migration by 1% while anti-C-terminus antibodies
reduced the Lumens by 60%, Branch Points by 32% and
Figure 1. IFI16 protein levels in patients’ and controls’ sera
determined using an in-house capture ELISA. Each dot represents
the concentration of IFI16 protein (expressed in ng/ml on a linear scale)
in each individual subject: patients suffering from Systemic Sclerosis
(SSc, n = 50), Systemic Lupus Erythematosus (SLE, n = 100), Sjogren’s
Syndrome (SjS, n = 49), Rheumatoid Arthritis (RA, n = 50), and non-SLE
glomerulonephritis (non-SLE GN n=46) were investigated together
with healthy controls (CTRL, n = 116). The horizontal bars represent the
median values. Values over the dotted line indicate the percentage of
subjects with IFI16 protein levels above the cut-off value (27 ng/ml)
calculated as the 95th percentile of the control population. Statistical
significance: *** p,0.001 vs. controls (Kruskall-Wallis test).
doi:10.1371/journal.pone.0063045.g001
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migration by 49%. This indicates the role of anti-N-terminus
antibody in inhibiting the activities of IFI16 toward endothelial
cells, restoring the tube formation and migratory activities.
Altogether, these results suggest that the IFI16 activity is specific
and that the functional domain resides at the N-terminus, where
the PYD domain is localized.
Binding of Extracellular IFI16 on the Plasma Membrane of
HUVEC
The finding that extracellular IFI16 impairs endothelial cell
functions, including tube morphogenesis and transwell migration
indicates a possible alarmin function as recently demonstrated for
Danger and Pathogen-associated molecular pattern molecules
collectively called as DAMPs, PAMPs such as autoantigen
HMGB-1 [38,39]. Thus to find evidence in this direction it was
important to evaluate the binding interaction of IFI16 on the
plasma membrane of HUVEC. A series of binding experiments
were conducted to verify the presence of high-affinity binding sites
in the membranes of the target cells. In the previous section, it has
been described that 25 mg/ml (300 nM) rIFI16 concentration is
non-toxic to HUVEC, while they can still perform biological
functions. Thus HUVEC were incubated with lowest concentra-
tions (10 nM, 20 nM, and 30 nM) of FITC-labeled rIFI16 to
avoid toxicity or apoptosis and the binding was visualized by
confocal microscopy. As shown in Figure 4A, binding of FITC-
labeled rIFI16 was detected at least concentration of 10 nM,
increased at 20 nM, and saturated at 30 nM. To avoid the non-
specific binding of rIFI16 with sugar residues on plasma
membrane, HUVEC were grown in presence of tunicamycin
which inhibits N-glycosylation of proteins. By contrast to above
findings, human fibroblasts were negative for FITC-labeled rIFI16
at all the rIFI16 concentrations investigated (data not shown).
Furthermore, to demonstrate that the binding of rIFI16 is of
physiological relevance, co-culturing experiments were organized
in such a way that UV-B irradiated cells release endogenous IFI16
[29] which in turn binds to neighboring HUVEC in the same
system. As shown in Figure 4B, after 24 h HUVEC were observed
to be surface bound with endogenous IFI16 released from HeLa
cells, while by 36 h this bound IFI16 entered the cytoplasm and by
48 h it almost disappeared. When fibroblasts were used instead of
HUVEC, the binding was not observed, while also when HUVEC
were cultured with normal HeLa cells, surface presence of IFI16
was not detected (data not shown).
Kinetics of rIFI16 Binding on Different Cell Lines
To get some insights into the binding characteristics of IFI16 to
different cell lines, binding kinetics experiments using radioiodin-
ated rIFI16 were performed. Specific binding was calculated as the
difference between total and non-specific binding. As shown in
Figure 5A, the specific binding of [125I]-rIFI16 to its binding site
on HUVEC is saturable and has a dissociation constant (Kd) equal
to 2.7 nM; 71.55 to 83.84 fmol of [125I]-rIFI16 was estimated to
saturate the binding sites on 105 HUVEC, thus the maximal
number of binding sites (Bmax) could be estimated to be in the
range of 250,000 to 450,000 binding sites/cell. Furthermore, the
binding of [125I]-rIFI16 on HUVEC was displaced by 10- to 100-
fold of unlabeled rIFI16, demonstrating its competitive nature
(Figure 5B). The inhibition constant (Ki) was calculated to be
14.43 nM and the half maximal inhibitory concentration (IC50)
was 67.88 nM. Similar results were obtained for HeLa and
HaCaT cell lines, which also indicated saturable and competitive
nature towards rIFI16 binding. As a negative control, human
dermal fibroblasts (HDF) and murine fibroblasts (3T3) were
accessed for specific and competitive binding of [125I]-rIFI16 in
parallel with HUVEC (Figure 5A and 5B). Both HDF and 3T3
were found to exhibit non-saturable rIFI16 binding, indicating the
lack of any specific IFI16 binding sites. Moreover, the binding of
rIFI16 on these cells was non-competitive in nature (Figure 5B).
Also as reported in Figure 5C, different cell lines shown variable
affinities towards IFI16 binding.
[125I]-rIFI16 Binding Inhibition by Anti-IFI16 Polyclonal
Antibodies
To evaluate the binding properties of rIFI16 to its receptor with
respect to epitope mapping, we performed a binding inhibition
assay using radioiodinated rIFI16 in the presence of increasing
concentrations of antibodies recognizing the IFI16 N-terminal
domain. As depicted in Figure 6, a gradual decrease in the bound
[125I]-rIFI16 was observed with increasing concentrations of
antibody (from 10 to 1000 nM). Conversely, the anti-IFI16
antibody recognizing the C-terminal domain (478–729 aa) was
not able to inhibit the binding of [125I]-rIFI16 to its receptor.
Together with the results from the functional assays, these
observations provide evidence indicating that the N-terminal
region of rIFI16 is required for its binding to the novel membrane
receptor on HUVEC and is responsible for its signal transduction
capacity.
Discussion
In the present study, we demonstrate for the first time: i) the
presence of significant levels of extracellular IFI16 protein in the
sera of patients affected by systemic autoimmune diseases,
including SSc, SjS, SLE and RA but not in non-SLE GN as
compared to healthy controls, and ii) that the extracellular IFI16
exerts biological effects on endothelial cells upon binding to a
specific cell surface receptor. These findings have important
implications as they provide novel insights into the role of IFI16 in
the pathogenesis of systemic autoimmune diseases. Various
research groups, including ours, have shown that following
transfection of virus-derived DNA [19,40], or treatment with
UVB [29], IFI16 delocalizes from the nucleus to the cytoplasm
and is then eventually released into the extracellular milieu.
Consistent with these observations, we now demonstrate the
presence of circulating IFI16 protein in the sera of patients affected
by systemic autoimmune diseases, but not in patients with non-
autoimmune inflammatory diseases like non-SLE GN. Skin
manifestations and vasculopathy are common components of a
number of autoimmune diseases and represent a significant source
of morbidity [41,42]. Thus, to investigate the hypothesis that
circulating IFI16 is able to exert harmful effects on target cells
in vivo, an in vitro cell model consisting of primary endothelial cells
Figure 2. Extracellular IFI16 affects various biological functions of primary endothelial cells. HUVEC were treated with different doses of
recombinant IFI16 protein (rIFI16), the same volumes of vehicle (Mock), or left untreated (NT) for 48 h. (A) Viability analysis (MTT assay); the viability of
control preparations (NT) was set to 100%. (B) Capillary-like tube formation assay (Matrigel). For a quantitative assessment of angiogenesis, the
number of lumens and branch points was assessed (upper panels); representative images of three independent experiments are reported (lower
panels). (C) Migration analysis (Transwell assay) results are reported as the percentage of migrated cells vs. untreated HUVECs. Values represent the
mean6SD of 3 independent experiments, (**p,0.01, ***p,0.001; one-way ANOVA followed by Bonferroni’s multiple comparison test).
doi:10.1371/journal.pone.0063045.g002
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(HUVEC) was used to test the activity of extracellular IFI16 on cell
functions. These experiments clearly demonstrate that extracellu-
lar IFI16 affects some biological processes of endothelial cells,
including tube morphogenesis and transwell migration. The
specificity of these effects was assessed by the addition of anti-
IFI16 antibodies which were able to neutralize the activity of the
protein blocking its inhibitory effects. Subsequently, the presence
of IFI16 in the extracellular environment could also be the main
Figure 3. Anti-IFI16 antibodies restore the biological activities of extracellular IFI16. HUVEC were treated for 48 h with different doses of
recombinant IFI16 protein (rIFI16), the same volumes of vehicle (Mock), or left untreated (NT), alone or in combination with antibodies against IFI16.
(A) Capillary-like tube formation assay (Matrigel). For a quantitative assessment of angiogenesis, the number of lumens and branch points was
assessed (upper panels); representative images of three independent experiments are reported (lower panels). (B) Migration analysis (Transwell assay)
results are reported as the percentage of migrated cells vs. untreated HUVECs. Values represent the mean6SD of 3 independent experiments
(**p,0.01, ***p,0.001, one-way ANOVA followed by Bonferroni’s multiple comparison test).
doi:10.1371/journal.pone.0063045.g003
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reason behind the presence of anti-IFI16 autoantibodies in
autoimmune patients’ sera. (Caneparo et al. Lupus 2013, accept-
ed) Together, these observations suggest the possible role of IFI16
in the clinical manifestation of autoimmune diseases, due to its
presence in the extracellular environment. Since IFI16 can be
released extracellularly which further reflect distinct extracellular
biological activities, it is an indication of a novel alarmin function
of this interferon inducible protein. Such stress-dependent
shuttling, release, binding to cell surface was described in the past
for autoantigen La/SS-B [43] and recently reviewed for HMGB1
protein [39] which upon release, binds to the cell surface receptors
of neighboring cells. Thus as part of alarmin function, we further
hypothesized that once released IFI16 protein must also bind
neighboring cells to communicate the stress signal. In this
direction, we assessed the affinity of IFI16 towards the plasma
membrane of HUVEC. Confocal images visualized patterned
binding of FITC labeled rIFI16 protein on the plasma membrane,
which gave us the first preliminary evidence of the existence of an
IFI16 interacting molecule which we suspect to be receptor-kind.
Furthermore, we found experimental evidence that endogenous
IFI16 protein released by dying cells bind neighboring cells. As a
consequence of this binding, time-lapse studies proved its further
entry into the cytoplasm. Moreover, such binding and transport of
IFI16 was observed in different cell lines with different affinities.
The experiments using radiolabeled IFI16 to investigate the
binding kinetics of IFI16 in the HUVEC provide strong evidence
supporting the presence of specific binding sites in the plasma
membrane through which IFI16 exerts its cytotoxic activity. These
binding sites were found to be saturable and competitive for IFI16,
while the binding experiments in HUVEC indicate the presence of
approximately 250,000 to 450,000 binding sites per cell, with a
dissociation constant (Kd) of 2.7 nM. Similar binding character-
Figure 4. Plasma membrane binding of IFI16 to HUVEC. (A) Cells were left untreated (a, negative control) or incubated with increasing
concentrations of FITC-labeled recombinant IFI16 (b, 10 nM rIFI16-FITC; c, 20 nM rIFI16-FITC; d, 30 nM rIFI16-FITC). Binding was detected by confocal
microscopy using an excitation wavelength of 490 nm for FITC in one channel and trans-illuminated light in the other. Representative images of three
independent experiments are shown. (B) Endogenous IFI16 released by irradiated HeLa cells binds neighboring HUVEC. UV-B irradiated HeLa cells
were co-cultured with HUVEC and after 24 h, 36 h and 48 h, dead cell debris were removed and immunofluorescence was performed on the
remaining live HUVEC using a home-made anti-IFI16 polyclonal as primary antibody and Alexa-488- anti-rabbit as secondary antibody. The cells were
then fixed, permeabilized, nuclear-stained using propidium iodide and analyzed by confocal microscopy. Fibroblasts were employed as negative
control. Representative images of three independent experiments are shown.
doi:10.1371/journal.pone.0063045.g004
Figure 5. Binding Kinetics of [125I]-rIFI16 on HUVEC, HDF, and 3T3 cells. (A) Specific binding of [125I]-rIFI16 on the plasma membrane of
HUVEC, HeLa, HACAT, HDF, and 3T3 cells. (B) Competitive binding of [125I]-rIFI16 on HUVEC, HeLa, HaCaT, HDF, and 3T3 cells. (C) The binding affinity
(Kd), total bound ligand (Bmax) and the estimated number of binding sites per cell for different cell lines. The experiment was carried out in triplicates
and data was analyzed using non-linear regression equations from GraphPad Prism with 95% confidence intervals. All the experiments have been
repeated at least three times and one representative is reported.
doi:10.1371/journal.pone.0063045.g005
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istics were shown by different epithelial cell lines while a
completely un-related cell line like fibroblasts demonstrated non-
specific binding. This explains the specificity of IFI16 binding
which is mostly restricted towards endothelium and epithelium.
Neutralization experiments employing antibodies directed against
different regions of the protein allowed us to demonstrate that the
N-terminus, containing the PYD domain, is responsible for
binding interaction. Consistent with this observation, the same
antibodies were able to neutralize the biological activity of
extracellular IFI16, as described earlier.
In summary, our results provide evidence for a novel alarmin
function of IFI16 protein which is overexpressed upon inflamma-
tory stimuli and then released in the extracellular environment.
Once released, IFI16 binds to neighboring cells propagating the
stress signal causing damage. The presence of anti-IFI16
autoantibodies have been detected in many autoimmune diseases
[25–28], thus the release of IFI16 in the extracellular milieu marks
the first step in the development of autoimmunity.
Acknowledgments
We gratefully acknowledge the help of Andrea Graziani and Gianluca
Baldanzi, Medical School of Novara for their guidance regarding the
receptor binding studies. We also thank Donato Colangelo, Medical School
of Novara, for helpful suggestions on evaluating binding kinetics data.
Finally, we thanks FIRMA group and Piero Stratta, Medical School of
Novara for giving us the patients’ sera.
Author Contributions
Conceived and designed the experiments: SL MG. Performed the
experiments: FG MB MDA VDO VC. Analyzed the data: FG MB
MDA VDO VC. Contributed reagents/materials/analysis tools: AT.
Wrote the paper: SL MG.
References
1. Elkon KB, Wiedeman A (2012) Type I IFN system in the development and
manifestations of SLE. Curr Opin Rheumatol 24: 499–505.
2. Pollard KM, Hultman P, Toomey CB, Cauvi DM, Hoffman HM, et al. (2012)
Definition of IFN-gamma-related pathways critical for chemically-induced
systemic autoimmunity. J Autoimmun 39: 323–331.
3. Choubey D, Moudgil KD (2011) Interferons in autoimmune and inflammatory
diseases: regulation and roles. J Interferon Cytokine Res 31: 857–865.
4. Crow MK (2010) Type I interferon in organ-targeted autoimmune and
inflammatory diseases. Arthritis Res Ther 12 Suppl 1: S5.
5. Ronnblom L (2010) Potential role of IFNalpha in adult lupus. Arthritis Res Ther
12 Suppl 1: S3.
6. Higgs BW, Liu Z, White B, Zhu W, White WI, et al. (2011) Patients with
systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma
share activation of a common type I interferon pathway. Ann Rheum Dis 70:
2029–2036.
7. Mavragani CP, Crow MK (2010) Activation of the type I interferon pathway in
primary Sjogren’s syndrome. J Autoimmun 35: 225–231.
8. Kong JS, Teuber SS, Gershwin ME (2006) Potential adverse events with biologic
response modifiers. Autoimmun Rev 5: 471–485.
9. Sozzani S, Bosisio D, Scarsi M, Tincani A (2010) Type I interferons in systemic
autoimmunity. Autoimmunity 43: 196–203.
10. Higgs BW, Zhu W, Richman L, Fiorentino DF, Greenberg SA, et al. (2012)
Identification of activated cytokine pathways in the blood of systemic lupus
erythematosus, myositis, rheumatoid arthritis, and scleroderma patients.
Int J Rheum Dis 15: 25–35.
11. Selmi C, Lleo A, Zuin M, Podda M, Rossaro L, et al. (2006) Interferon alpha
and its contribution to autoimmunity. Curr Opin Investig Drugs 7: 451–456.
12. Bach JF (2005) Infections and autoimmune diseases. J Autoimmun 25 Suppl:
74–80.
13. Cridland JA, Curley EZ, Wykes MN, Schroder K, Sweet MJ, et al. (2012) The
mammalian PYHIN gene family: phylogeny, evolution and expression. BMC
Evol Biol 12: 140.
14. Gariglio M, Mondini M, De Andrea M, Landolfo S (2011) The multifaceted
interferon-inducible p200 family proteins: from cell biology to human pathology.
J Interferon Cytokine Res 31: 159–172.
15. Gariglio M, Azzimonti B, Pagano M, Palestro G, De Andrea M, et al. (2002)
Immunohistochemical expression analysis of the human interferon-inducible
gene IFI16, a member of the HIN200 family, not restricted to hematopoietic
cells. J Interferon Cytokine Res 22: 815–821.
16. Cristea IM, Moorman NJ, Terhune SS, Cuevas CD, O’Keefe ES, et al. (2010)
Human cytomegalovirus pUL83 stimulates activity of the viral immediate-early
promoter through its interaction with the cellular IFI16 protein. J Virol 84:
7803–7814.
17. Li T, Diner BA, Chen J, Cristea IM (2012) Acetylation modulates cellular
distribution and DNA sensing ability of interferon-inducible protein IFI16. Proc
Natl Acad Sci U S A 109: 10558–10563.
18. Gariano GR, Dell’Oste V, Bronzini M, Gatti D, Luganini A, et al. (2012) The
intracellular DNA sensor IFI16 gene acts as restriction factor for human
cytomegalovirus replication. PLoS Pathog 8: e1002498.
19. Unterholzner L, Bowie AG (2011) Innate DNA sensing moves to the nucleus.
Cell Host Microbe 9: 351–353.
20. Sponza S, De Andrea M, Mondini M, Gugliesi F, Gariglio M, et al. (2009) Role
of the interferon-inducible IFI16 gene in the induction of ICAM-1 by TNF-
alpha. Cell Immunol 257: 55–60.
21. Gugliesi F, Mondini M, Ravera R, Robotti A, de Andrea M, et al. (2005) Up-
regulation of the interferon-inducible IFI16 gene by oxidative stress triggers p53
transcriptional activity in endothelial cells. J Leukoc Biol 77: 820–829.
22. Mondini M, Costa S, Sponza S, Gugliesi F, Gariglio M, et al. (2010) The
interferon-inducible HIN-200 gene family in apoptosis and inflammation:
implication for autoimmunity. Autoimmunity 43: 226–231.
23. Gugliesi F, De Andrea M, Mondini M, Cappello P, Giovarelli M, et al. (2010)
The proapoptotic activity of the Interferon-inducible gene IFI16 provides new
insights into its etiopathogenetic role in autoimmunity. J Autoimmun 35: 114–
123.
24. Caposio P, Gugliesi F, Zannetti C, Sponza S, Mondini M, et al. (2007) A novel
role of the interferon-inducible protein IFI16 as inducer of proinflammatory
molecules in endothelial cells. J Biol Chem 282: 33515–33529.
25. Rekvig OP, Putterman C, Casu C, Gao HX, Ghirardello A, et al. (2012)
Autoantibodies in lupus: culprits or passive bystanders? Autoimmun Rev 11:
596–603.
26. Mondini M, Vidali M, Airo P, De Andrea M, Riboldi P, et al. (2007) Role of the
interferon-inducible gene IFI16 in the etiopathogenesis of systemic autoimmune
disorders. Ann N Y Acad Sci 1110: 47–56.
27. Mondini M, Vidali M, De Andrea M, Azzimonti B, Airo P, et al. (2006) A novel
autoantigen to differentiate limited cutaneous systemic sclerosis from diffuse
cutaneous systemic sclerosis: the interferon-inducible gene IFI16. Arthritis
Rheum 54: 3939–3944.
Figure 6. Binding inhibition of [125I]-rIFI16 using anti-IFI16
polyclonal antibodies. Antibody inhibition curve of HUVEC using
anti-rIFI16 N-terminal (1–205 aa) polyclonal antibodies (dashed) and C-
term polyclonal antibodies (dot-dashed). Competitive binding of rIFI16
and [125I]-rIFI16 to HUVEC (plain) was used as the control condition. The
experiment was carried out in triplicates and data was analyzed using
non-linear regression equations from GraphPad Prism with 95%
confidence intervals. All the experiments have been repeated at least
three times and one representative is reported.
doi:10.1371/journal.pone.0063045.g006
Extracellular IFI16 Protein as Signal of Damage
PLOS ONE | www.plosone.org 10 May 2013 | Volume 8 | Issue 5 | e63045
28. Costa S, Mondini M, Caneparo V, Afeltra A, Airo P, et al. (2011) Detection of
anti-IFI16 antibodies by ELISA: clinical and serological associations in systemic
sclerosis. Rheumatology (Oxford) 50: 674–681.
29. Costa S, Borgogna C, Mondini M, De Andrea M, Meroni PL, et al. (2011)
Redistribution of the nuclear protein IFI16 into the cytoplasm of ultraviolet B-
exposed keratinocytes as a mechanism of autoantigen processing. Br J Dermatol
164: 282–290.
30. Schattgen SA, Fitzgerald KA (2011) The PYHIN protein family as mediators of
host defenses. Immunol Rev 243: 109–118.
31. Baggetta R, De Andrea M, Gariano GR, Mondini M, Ritta M, et al. (2010) The
interferon-inducible gene IFI16 secretome of endothelial cells drives the early
steps of the inflammatory response. Eur J Immunol 40: 2182–2189.
32. Pauwels R, Balzarini J, Baba M, Snoeck R, Schols D, et al. (1988) Rapid and
automated tetrazolium-based colorimetric assay for the detection of anti-HIV
compounds. J Virol Methods 20: 309–321.
33. Gugliesi F, Dell’oste V, De Andrea M, Baggetta R, Mondini M, et al. (2011)
Tumor-derived endothelial cells evade apoptotic activity of the interferon-
inducible IFI16 gene. J Interferon Cytokine Res 31: 609–618.
34. Koristka S, Cartellieri M, Arndt C, Bippes CC, Feldmann A, et al. (2013)
Retargeting of regulatory T cells to surface-inducible autoantigen La/SS-B.
J Autoimmun In press.
35. Imai Y, Leung CK, Friesen HG, Shiu RP (1982) Epidermal growth factor
receptors and effect of epidermal growth factor on growth of human breast
cancer cells in long-term tissue culture. Cancer Res 42: 4394–4398.
36. Coleman JW, Godfrey RC (1981) The number and affinity of IgE receptors on
dispersed human lung mast cells. Immunology 44: 859–863.
37. Guiducci S, Distler O, Distler JH, Matucci-Cerinic M (2008) Mechanisms of
vascular damage in SSc–implications for vascular treatment strategies.
Rheumatology (Oxford) 47 Suppl 5: v18–20.
38. Bianchi ME (2007) DAMPs, PAMPs and alarmins: all we need to know about
danger. J Leukoc Biol 81: 1–5.
39. Harris HE, Andersson U, Pisetsky DS (2012) HMGB1: a multifunctional
alarmin driving autoimmune and inflammatory disease. Nat Rev Rheumatol 8:
195–202.
40. Keating SE, Baran M, Bowie AG (2011) Cytosolic DNA sensors regulating type
I interferon induction. Trends Immunol 32: 574–581.
41. Kaplan MJ (2009) Endothelial damage and autoimmune diseases. Autoimmu-
nity 42: 561–562.
42. Rashtak S, Pittelkow MR (2008) Skin involvement in systemic autoimmune
diseases. Curr Dir Autoimmun 10: 344–358.
43. Bachmann M, Zaubitzer T, Muller WE (1992) The autoantigen La/SSB:
detection on and uptake by mitotic cells. Exp Cell Res 201: 387–398.
Extracellular IFI16 Protein as Signal of Damage
PLOS ONE | www.plosone.org 11 May 2013 | Volume 8 | Issue 5 | e63045
